AZD0120 Clinical Trials
7 recruitingBiologic
Phase 15Phase 23Phase 31Early Phase 11
Showing 1–7 of 7 trials
Recruiting
Phase 1
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
Multiple Myeloma
AstraZeneca40 enrolled13 locationsNCT07073547
Recruiting
Phase 1Phase 2
A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
Lupus Erythematosus, Systemic
AstraZeneca150 enrolled18 locationsNCT06897930
Recruiting
Phase 1Phase 2
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Relapsed/Refractory Multiple Myeloma
AstraZeneca182 enrolled36 locationsNCT05850234
Recruiting
Phase 1
A Study of AZD0120 in Autoimmune Diseases
Rheumatoid ArthritisIdiopathic Inflammatory MyopathiesSystemic Sclerosis
AstraZeneca27 enrolled18 locationsNCT07295847
Recruiting
Phase 3
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Relapsed/Refractory Multiple Myeloma
AstraZeneca508 enrolled111 locationsNCT07391657
Recruiting
Early Phase 1
CAR-T Therapy Targeting CD19 and BCMA in Highly Sensitized Kidney Transplant Participants
Highly Sensitized Patients Awaiting Kidney Transplant
Tongji Hospital12 enrolled1 locationNCT07350837
Recruiting
Phase 1Phase 2
A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
AmyloidosisLight Chain AmyloidosisRelapsed AL Amyloidosis+1 more
Alexion Pharmaceuticals, Inc.91 enrolled18 locationsNCT07081646